These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 21397026)

  • 1. Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of mucopolysaccharidosis type I.
    Wolf DA; Lenander AW; Nan Z; Belur LR; Whitley CB; Gupta P; Low WC; McIvor RS
    Neurobiol Dis; 2011 Jul; 43(1):123-33. PubMed ID: 21397026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal Adeno-Associated Virus Mediated Gene Delivery and Expression of Human Iduronidase in the Central Nervous System: A Noninvasive and Effective Approach for Prevention of Neurologic Disease in Mucopolysaccharidosis Type I.
    Belur LR; Temme A; Podetz-Pedersen KM; Riedl M; Vulchanova L; Robinson N; Hanson LR; Kozarsky KF; Orchard PJ; Frey WH; Low WC; McIvor RS
    Hum Gene Ther; 2017 Jul; 28(7):576-587. PubMed ID: 28462595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurologic Recovery in MPS I and MPS II Mice by AAV9-Mediated Gene Transfer to the CNS After the Development of Cognitive Dysfunction.
    Podetz-Pedersen KM; Laoharawee K; Singh S; Nguyen TT; Smith MC; Temme A; Kozarsky K; McIvor RS; Belur LR
    Hum Gene Ther; 2023 Jan; 34(1-2):8-18. PubMed ID: 36541357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Endovascular and Intraventricular Gene Therapy With Adeno-Associated Virus-α-L-Iduronidase for Hurler Disease.
    Janson CG; Romanova LG; Leone P; Nan Z; Belur L; McIvor RS; Low WC
    Neurosurgery; 2014 Jan; 74(1):99-111. PubMed ID: 24077583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-L-iduronidase gene.
    Hartung SD; Frandsen JL; Pan D; Koniar BL; Graupman P; Gunther R; Low WC; Whitley CB; McIvor RS
    Mol Ther; 2004 Jun; 9(6):866-75. PubMed ID: 15194053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neonatal Systemic AAV Induces Tolerance to CNS Gene Therapy in MPS I Dogs and Nonhuman Primates.
    Hinderer C; Bell P; Louboutin JP; Zhu Y; Yu H; Lin G; Choa R; Gurda BL; Bagel J; O'Donnell P; Sikora T; Ruane T; Wang P; Tarantal AF; Casal ML; Haskins ME; Wilson JM
    Mol Ther; 2015 Aug; 23(8):1298-1307. PubMed ID: 26022732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose enzyme replacement therapy in murine Hurler syndrome.
    Ou L; Herzog T; Koniar BL; Gunther R; Whitley CB
    Mol Genet Metab; 2014 Feb; 111(2):116-22. PubMed ID: 24100243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model.
    Visigalli I; Delai S; Politi LS; Di Domenico C; Cerri F; Mrak E; D'Isa R; Ungaro D; Stok M; Sanvito F; Mariani E; Staszewsky L; Godi C; Russo I; Cecere F; Del Carro U; Rubinacci A; Brambilla R; Quattrini A; Di Natale P; Ponder K; Naldini L; Biffi A
    Blood; 2010 Dec; 116(24):5130-9. PubMed ID: 20847202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RTB lectin-mediated delivery of lysosomal α-l-iduronidase mitigates disease manifestations systemically including the central nervous system.
    Ou L; Przybilla MJ; Koniar B; Whitley CB
    Mol Genet Metab; 2018 Feb; 123(2):105-111. PubMed ID: 29198892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro gene therapy of mucopolysaccharidosis type I by lentiviral vectors.
    Di Natale P; Di Domenico C; Villani GR; Lombardo A; Follenzi A; Naldini L
    Eur J Biochem; 2002 Jun; 269(11):2764-71. PubMed ID: 12047386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of neonatal administration of a retroviral vector expressing alpha-L-iduronidase upon lysosomal storage in brain and other organs in mucopolysaccharidosis I mice.
    Chung S; Ma X; Liu Y; Lee D; Tittiger M; Ponder KP
    Mol Genet Metab; 2007 Feb; 90(2):181-92. PubMed ID: 16979922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene therapy for canine alpha-L-iduronidase deficiency: in utero adoptive transfer of genetically corrected hematopoietic progenitors results in engraftment but not amelioration of disease.
    Lutzko C; Omori F; Abrams-Ogg AC; Shull R; Li L; Lau K; Ruedy C; Nanji S; Gartley C; Dobson H; Foster R; Kruth S; Dubé ID
    Hum Gene Ther; 1999 Jun; 10(9):1521-32. PubMed ID: 10395377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracerebroventricular transplantation of human bone marrow-derived multipotent progenitor cells in an immunodeficient mouse model of mucopolysaccharidosis type I (MPS-I).
    Nan Z; Shekels L; Ryabinin O; Evavold C; Nelson MS; Khan SA; Deans RJ; Mays RW; Low WC; Gupta P
    Cell Transplant; 2012; 21(7):1577-93. PubMed ID: 22472595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Normalization and improvement of CNS deficits in mice with Hurler syndrome after long-term peripheral delivery of BBB-targeted iduronidase.
    El-Amouri SS; Dai M; Han JF; Brady RO; Pan D
    Mol Ther; 2014 Dec; 22(12):2028-2037. PubMed ID: 25088464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retroviral-vector-mediated gene therapy to mucopolysaccharidosis I mice improves sensorimotor impairments and other behavioral deficits.
    Baldo G; Wozniak DF; Ohlemiller KK; Zhang Y; Giugliani R; Ponder KP
    J Inherit Metab Dis; 2013 May; 36(3):499-512. PubMed ID: 22983812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice.
    Baldo G; Mayer FQ; Martinelli BZ; de Carvalho TG; Meyer FS; de Oliveira PG; Meurer L; Tavares A; Matte U; Giugliani R
    Mol Genet Metab; 2013 May; 109(1):33-40. PubMed ID: 23562162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector.
    Kobayashi H; Carbonaro D; Pepper K; Petersen D; Ge S; Jackson H; Shimada H; Moats R; Kohn DB
    Mol Ther; 2005 May; 11(5):776-89. PubMed ID: 15851016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver-directed gene therapy corrects cardiovascular lesions in feline mucopolysaccharidosis type I.
    Hinderer C; Bell P; Gurda BL; Wang Q; Louboutin JP; Zhu Y; Bagel J; O'Donnell P; Sikora T; Ruane T; Wang P; Haskins ME; Wilson JM
    Proc Natl Acad Sci U S A; 2014 Oct; 111(41):14894-9. PubMed ID: 25267637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neonatal nonviral gene editing with the CRISPR/Cas9 system improves some cardiovascular, respiratory, and bone disease features of the mucopolysaccharidosis I phenotype in mice.
    Schuh RS; Gonzalez EA; Tavares AMV; Seolin BG; Elias LS; Vera LNP; Kubaski F; Poletto E; Giugliani R; Teixeira HF; Matte U; Baldo G
    Gene Ther; 2020 Feb; 27(1-2):74-84. PubMed ID: 31827259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neonatal combination therapy improves some of the clinical manifestations in the Mucopolysaccharidosis type I murine model.
    Santi L; De Ponti G; Dina G; Pievani A; Corsi A; Riminucci M; Khan S; Sawamoto K; Antolini L; Gregori S; Annoni A; Biondi A; Quattrini A; Tomatsu S; Serafini M
    Mol Genet Metab; 2020 Jul; 130(3):197-208. PubMed ID: 32439268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.